



**PREVECEUTICAL MEDICAL INC.**  
Suite 2200, 1177 West Hastings Street  
Vancouver, British Columbia V6E 2K3

FOR IMMEDIATE RELEASE

News Release

September 15, 2017

### **PreveCeutical Launches New Corporate Website**

Vancouver, British Columbia: PreveCeutical Medical Inc. (the “**Company**” or “**PreveCeutical**”) (CSE: PREV, OTC: PRVCF, FSE: 18H) is pleased to announce the launch of a new corporate website – [www.PreveCeutical.com](http://www.PreveCeutical.com).

The new website has been optimized to cater to both desktop and mobile users. In an organized layout, visitors across all platforms are able to efficiently access information on PreveCeutical’s innovative research and development programs, its CELLB9<sup>®</sup> immune boosting product, and other corporate information.

PreveCeutical’s Chairman and CEO, Mr. Stephen Van Deventer commented, “The new website will provide ease of access to information and products for customers, investors, partners and media in an organized and robust platform. We believe that this new site will allow our visitors to have a very informative experience as we continue to grow and increase our market presence.”

#### ***About PreveCeutical Medical Inc.***

PreveCeutical is a health sciences company that develops innovative preventive therapies utilizing organic and nature identical products.

PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel platform for nose to brain delivery of medical compounds including cannabinoids; Nature Identical<sup>™</sup> peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

PreveCeutical sells CELLB9<sup>®</sup>, an Immune System Booster. CELLB9<sup>®</sup> is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom.

For more information about PreveCeutical, please visit <https://preveceutical.com/>, follow us on Twitter: <https://twitter.com/PreveCeuticals> and Facebook: [www.facebook.com/PreveCeutical](http://www.facebook.com/PreveCeutical).

## ***On Behalf of the Board of Directors***

*“Stephen Van Deventer”*  
Chairman & CEO

### ***For further information, please contact:***

Deanna Kress  
Director of Corporate Communications & Investor Relations  
+1-778-999-6063  
deanna@PreveCeutical.com

### ***Forward-Looking Statements:***

This news release includes certain statements that constitute “forward-looking information” within the meaning of applicable Canadian securities laws. Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements. Statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future. Often, but not always, forward-looking statements can be identified by words such as “pro forma”, “plans”, “expects”, “may”, “should”, “budget”, “schedules”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “potential” or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Such forward-looking statements include, among others, statements as to the Company's research and development programs, and the Company's ability and success in executing its proposed business plans. Actual results could differ from those projected in any forward-looking statements due to numerous factors including risks and uncertainties relating to the inability of the Company, to, among other things, complete the proposed research project as planned or the inability of the Company to obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorisations required, including Canadian Securities Exchange acceptance of any planned future activities, or obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industry, may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company's filings are available at [www.sedar.com](http://www.sedar.com).

Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.